HRP20180621T1 - Postupak smanjivanja simptoma sličnih gripi, povezan s intramuskularnom primjenom interferona uz upotrebu režima rastuće doze uz brzo titranje - Google Patents

Postupak smanjivanja simptoma sličnih gripi, povezan s intramuskularnom primjenom interferona uz upotrebu režima rastuće doze uz brzo titranje

Info

Publication number
HRP20180621T1
HRP20180621T1 HRP20180621TT HRP20180621T HRP20180621T1 HR P20180621 T1 HRP20180621 T1 HR P20180621T1 HR P20180621T T HRP20180621T T HR P20180621TT HR P20180621 T HRP20180621 T HR P20180621T HR P20180621 T1 HRP20180621 T1 HR P20180621T1
Authority
HR
Croatia
Prior art keywords
influenzes
interferones
procedure
similar
increasing doses
Prior art date
Application number
HRP20180621TT
Other languages
English (en)
Croatian (hr)
Inventor
Aaron Deykin
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of HRP20180621T1 publication Critical patent/HRP20180621T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
HRP20180621TT 2011-03-15 2012-03-15 Postupak smanjivanja simptoma sličnih gripi, povezan s intramuskularnom primjenom interferona uz upotrebu režima rastuće doze uz brzo titranje HRP20180621T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP12719487.6A EP2686002B1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (1)

Publication Number Publication Date
HRP20180621T1 true HRP20180621T1 (hr) 2018-07-27

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180621TT HRP20180621T1 (hr) 2011-03-15 2012-03-15 Postupak smanjivanja simptoma sličnih gripi, povezan s intramuskularnom primjenom interferona uz upotrebu režima rastuće doze uz brzo titranje

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp 2室型プレフィルドシリンジ
US8932265B2 (en) * 2003-01-30 2015-01-13 Becton, Dickinson And Company Holder with safety shield for a drug delivery device
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
EP2686002B1 (en) 2018-01-24
ES2666850T3 (es) 2018-05-08
MX359947B (es) 2018-10-17
NZ712273A (en) 2016-09-30
HUE036931T2 (hu) 2018-08-28
KR20140038383A (ko) 2014-03-28
IL228425A0 (en) 2013-12-31
AU2012229104B2 (en) 2017-03-16
SG193446A1 (en) 2013-10-30
DK2686002T3 (en) 2018-04-30
EA201301024A1 (ru) 2014-03-31
BR112013023609A2 (pt) 2016-12-06
NZ616536A (en) 2015-10-30
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
SI2686002T1 (en) 2018-06-29
AU2012229104A1 (en) 2013-10-03
US20170360890A1 (en) 2017-12-21
US9198955B2 (en) 2015-12-01
ZA201306933B (en) 2016-07-27
IL228425A (en) 2017-08-31
EP2686002A1 (en) 2014-01-22
PT2686002T (pt) 2018-04-23
US20120237479A1 (en) 2012-09-20
JP6522069B2 (ja) 2019-05-29
JP6279905B2 (ja) 2018-02-14
WO2012125809A1 (en) 2012-09-20
US20160101157A1 (en) 2016-04-14
CY1120176T1 (el) 2018-12-12
JP2014508174A (ja) 2014-04-03
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
LT2686002T (lt) 2018-05-10
KR102050339B1 (ko) 2019-11-29
MX2013010507A (es) 2014-04-30
CA2846786C (en) 2022-05-17
US10500254B2 (en) 2019-12-10
CN103702680A (zh) 2014-04-02
US20250276042A1 (en) 2025-09-04
SMT201800221T1 (it) 2018-07-17
EA028448B1 (ru) 2017-11-30
PL2686002T3 (pl) 2018-10-31
JP2018030847A (ja) 2018-03-01
US20220280610A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
UA28786S (uk) Гідравлічний фітинг затискуваний вручну
PT2686347T (pt) Anticorpos dirigidos contra cd70
CR20140034A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
DK3196202T3 (da) Heterocyclylaminer som pi3k-inhibitorer
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
BR112014012159A2 (pt) tetra-hidrocanabivarina fitocanabinóide
DK2661243T3 (da) Konstruktioner, opnåede ved vævsteknologi
DK3195793T3 (da) Forbedringer i eller relateret til oftalmologi
EP2692421A4 (en) COMPOSITE MEMBRANE
CO6890100A2 (es) Tratamientos de combinación para hepatitis c
BR112014013034A2 (pt) método para produzir um anticorpo
BR302012002584S1 (pt) Configuracao aplicada em inalador
EP2739536A4 (en) IMPROVEMENTS RELATING TO PRINTING
EP2678305A4 (en) CHALCONE DERIVATIVES AS NRF2 ACTIVATORS
BR112013014846A2 (pt) processo para produzir macarrão instantâneo
UY33909A (es) Metodo para producir fibra de lignina
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
EP2766001A4 (en) Buffered Therapeutic Oxygen Composition
DK3156505T3 (da) Komplekse sæt af mirna'er som ikke-invasive biomarkører til coloncancer
DK2667895T3 (da) Anvendelse af mindst en p75ntr-receptor-inhibitor, alene eller i forbindelse med mindst en trka-receptor-aktivator, eller af mindst en trka-receptor-aktivator til behandling af kroniske inflammatoriske sygdomme
FR2975416B1 (fr) Support de lestage par dallette
DK2583571T3 (da) Forbedringer i forbindelse med skødeskind
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
EP2773202A4 (en) GAMMASEKRETASEMODULATOREN